Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
May 9, 2024 5:00 PM EDT
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an... More
May 8, 2024 4:05 PM EDT
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients
Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025
Expanded sales force on-track to be in the field by the end of the third quarter 2024
Strengthened financial position with an approximately $108 million public equity offering and $200 million financing commitment
...
More
